Seeking Alpha

Seeking Alpha Portfolio App for iPad

1,620 people get CUR articles and Market Currents by email alert.

Get email alerts on CUR »

CUR

Neuralstem, Inc.

5/18/2013, 7:16 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 10:46 AM Shares of stem cell research firms are rallying today on the back of an announcement today by the Oregon Health and Science University that they've successfully reproduced human stem cells by cloning. Cloning stem cells in this fashion could lead to cell therapies using a patient’s own cells and thereby avoid the problems of immune suppression: StemCells (STEM +2.2%), NeuralStem (CUR +2.1%), NeoStem (NBS +2.2%). Comment! [Healthcare, On the Move]
Friday, May 10, 4:31 PM Neuralstem (CUR): Q1 EPS of -$0.05 in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, April 22, 9:46 AM Neuralstem (CUR +2.7%-) ticks higher at the open after the FDA gives the go ahead to begin dosing its third and final cohort of patients in its ongoing Phase Ib safety trials of NSI-189, a treatment for major depressive disorder. Comment! [Healthcare, On the Move]
Friday, April 19, 12:31 PM Neuralstem (CUR +2.7%-) ticks higher at the open after the FDA gives the go ahead to begin dosing its third and final cohort of patients in its ongoing Phase Ib safety trials of NSI-189, a treatment for major depressive disorder.
2 Comments [Earnings, On the Move, Consumer, Global & FX]
Wednesday, April 17, 9:19 AM Neuralstem (CUR) is set to open sharply higher after saying the FDA has approved the company's request to begin a Phase II trial of NSI-566 human neural stem cells for the treatment of Lou Gehrig's disease. A Phase I study suggested the therapy interrupted the progression of the disease. Shares +11.32% Comment! [Healthcare, On the Move]
Wednesday, April 17, 9:12 AM Premarket gainers: VRML +29%. ACUR +26%. OCZ +18%. CUR +9%. ALKS +9%. ABMD +9%. ASML +6%.
Losers: EOPN -29%. INWK -25%. CXW -15%. MHR -12%. ZGNX -11%. TXT -9%. CRUS -7%. VRNG -6%. 1 Comment [On the Move]
Monday, March 25, 3:43 PM Neuralstem (CUR -2.7%) slips after earlier saying it's secured $8M in debt financing from Hercules Technology to fund the company's capital budget through late 2014. The company has multiple cell therapy clinical trials planned this year, including upcoming Phase 2 ALS trials in the U.S. Comment! [Healthcare, On the Move]
Monday, January 14, 9:41 AM Neuralstem (CUR) jumps 12.1% after it receives approval from the FDA to start a Phase I safety trial of its lead cell therapy treatment, NSI-566, in eight patients who have become complete paralyzed due to spinal-cord injuries. Neuralstem has already conducted 18 successful surgeries using the same cells and surgical device that it will use in the new trial. (PR) Comment! [On the Move, Healthcare]
Monday, January 14, 9:09 AM Premarket gainers: AZK +29%. CUR +14%. AVNW +13%. HWD +11%. VRNT +10%. NICE +8%. FIO +6%. FRAN +6%. DNDN +5%. ALU +6%.
Losers: NTE -11%. CRUS -6%. Comment! [On the Move]
Friday, December 7, 2012, 12:50 PM Midday top 10 gainers: CBMX +184%. GTIM +48%. LTBR +18%. DLGC +17%. RECV +16%. UNXL +15%. PAMT +15%. TELK +14%. JKS +14%. XPLR +11%.
Midday top 10 Losers: TOPS -23%. AMRN -19%. KUTV -15%. VTSS -13%. MBLX -11%. CHLN -11%. CHTP -9%. RGC -8%. CUR -8%. AACC -8%. Comment! [On the Move]
Tuesday, December 4, 2012, 12:45 PM Midday top 10 gainers: ALDA +54%. SINO +29%. CYCC +17%. LTBR +12%. CORT +12%. SAB +11%. EDMC +10%. CPGI +11%. PRIS +10%. ACLS +10%.
Midday top 10 Losers: UEPS -56%. GERN -24%. EXA -22%. CUR -20%. SSN -19%. PPHM -16%. IQNT -18%. PBY -14%. GURE -12%. LEDS -12%. 3 Comments [On the Move]
Monday, December 3, 2012, 2:28 PM Neuralstem (CUR +7.2%) spikes, possibly related to a Crain's article reporting "amazing results" in a patient who received 500K stem cells derived by CUR. 1 Comment [On the Move, Healthcare]
Tuesday, November 27, 2012, 12:45 PM Midday top 10 gainers: ACAD +141%. CPSL +30%. IMMR +30%. RAH +27%. TSPT +12%. BWEN +12%. CUR +12%. FOLD +10%. FONR +10%. CDTI +10%. Midday top 10 Losers: STV -11%. MMR -9%. THO -11%. RECV -10%. CBAK -9%. BLIN -12%. ENMD -8%. RGDX -8%. ARCI -8%. BV -8%. Comment!
Wednesday, October 17, 2012, 10:35 AM Neuralstem (CUR +0.9%) starts testing the safety of its NSI-189 treatment for Major Depressive Disorder on a second set of patients after receiving FDA approval to do so. "There were no surprises" in the first cohort of patients in the Phase Ib study, the company says. (PR) Comment! [Healthcare]
Tuesday, October 16, 2012, 9:10 AM Premarket gainers: NOOF +54%. THLD +12%. MUR +8%. AEGR +7%. JOEZ +7%. CUR +7%. DPZ +6%.
Losers: RATE -26%. ISIS -20%. CLWR -19%. CMRE -10%. WAC -5%. GWW -5%. 1 Comment [On the Move]
Monday, October 15, 2012, 3:16 PM Neuralstem (CUR +7.3%) pops after releasing positive results for its NSI-566 study, a spinal cord-derived neural stem cell line tested in a rat model of ischemic stroke. The data showed significant improvement in both motor and neurological tests, with the rats treated with the highest dose showing the most significant improvement in both categories. 3 Comments [Healthcare, On the Move]